Duration of Antibiotic Treatment for Early VAP (DATE) Trial



Status:Suspended
Conditions:Pneumonia, Pneumonia
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:December 2013
End Date:March 2020

Use our guide to learn which trials are right for you!

A Randomized Clinical Trial of 4 vs. 8 Days of Definitive Antibiotic Therapy for Early Ventilator-Associated Pneumonia in the Surgical Intensive Care Unit

Hypothesis: 4 days of antibiotic therapy, as compared to 8 days, is equally effective and
results in decreased antibiotic exposure among surgical ICU patients with early VAP.

The prevalence of multi-drug resistant (MDR) pathogens in intensive care units (ICUs)
worldwide has reached epidemic proportions. In some cases, the choice of potential therapy is
limited or even non-existent. Antibiotic prescription, through selection pressure, represents
the main mechanism by which resistance emerges. Limitations in the development of new
antibiotics underscores the importance of adherence to the principles of antibiotic
stewardship.

Ventilator associated pneumonia (VAP) is the most common serious infection in mechanically
ventilated, critically ill patients. Approximately one half of antibiotic prescription in the
ICU is related to VAP, including prophylactic, empiric, and definitive therapy. The
development of evidence-based algorithms for the rational use of antibiotics in the
management of patients with both suspected and confirmed VAP is pivotal to decreasing the
emergence of MDR pathogens.

Shortening the duration of antimicrobial therapy for VAP represents one strategy to curtail
the emergence of MDR pathogens. Although current guidelines recommend a treatment course of
8-14 days, both clinical and microbiologic resolution (MR) of infection typically occur much
sooner [10, 11]. In one study of ICU patients ventilated for > 5 days who developed VAP, 8
days of antimicrobial therapy was equally as effective as 14 days, provided VAP was not
caused by a non-lactose fermenting gram negative bacillus. Favorable results following
shorter courses of therapy for VAP have been observed, albeit in small, uncontrolled series.

One subset of patients for whom a decreased duration of antimicrobial therapy may be
particularly effective is those who develop VAP ≤ 5 days after intubation (early VAP). Early
VAP comprises approximately one half of cases of pneumonia diagnosed in the ICU. Furthermore,
as compared to patients who develop late VAP, patients who develop early VAP are more likely
to be infected with community-acquired pathogens sensitive to narrow spectrum antibiotics.
Finally, nearly all cases of early VAP caused by sensitive pathogens demonstrate MR after
relatively short (3-5 days) courses of therapy.

Inclusion Criteria:

1. Surgical patient

2. VAP, defined as clinical suspicion plus a bronchoalveolar lavage (BAL) culture showing
≥105 cfu/mL of at least one pathogen. The quantitative microbiology threshold will be
lowered to ≥104 cfu/mL if the patient was being treated with antibiotics to which the
pathogen is sensitive at the time of the BAL. Clinical suspicion of VAP is defined as
at least one point for ≥ 2 variables in the Clinical Pulmonary Infection Score (CPIS,
described below).

3. Ventilated ≤ 5 days at the time that the BAL was obtained.

4. Hospital LOS ≤ 5 days at the time that the BAL was obtained.

Exclusion Criteria:

1. Age < 18 years.

2. Prior episode of VAP for the index admission (the patient may have had prior BALs sent
for culture, but these cannot have met the above mentioned diagnostic criteria for
VAP).

3. VAP caused by a MDR pathogen: Early VAP is rarely caused by a MDR pathogen; in a
recent analysis of our surgical ICU, 94% of cases of early VAP were caused by a highly
sensitive pathogen (MSSA 39%, H flu 35%, S. pneumo 16%, E. coli 9%) (Pieracci in
press). Patients with early VAP caused by the following MDR pathogens will be
excluded: Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-intermediate
Staphylococcus aureus (VISA), pseudomonas aeruginosa, Vancomycin-resistant
enterococcus (VRE), Acinetobacter baumannii, Stenotrophomonas maltophilia, and
extended-spectrum beta lactamase producing gram negative bacilli.

4. Antibiotic therapy for ≥ 5 of the last 10 days preceding the BAL.

5. Septic shock, defined as evidence of tissue hypoperfusion after adequate volume
expansion, due to infection, and requiring ≥ 1 vasopressor.

6. Current or recent (within 30 days) use of immunosuppressive medications.

7. Length of stay ≥ 48 hours in a transferring facility.

8. Inpatient hospitalization within 30 days of admission.

9. Pregnancy or lactation.

10. Legal arrest or incarceration.

11. Moribund state in which death is imminent.
We found this trial at
1
site
777 Bannock St
Denver, Colorado 80204
(303) 436-6000
Principal Investigator: Fredric M Pieracci, MD, MPH
Phone: 303-436-4029
Denver Health Medical Center Denver Health is a comprehensive, integrated organization providing level one care...
?
mi
from
Denver, CO
Click here to add this to my saved trials